Last reviewed · How we verify
SCTB14
SCTB14 is a small molecule targeting the CD47/SIRPα axis.
SCTB14 is a small molecule targeting the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | SCTB14 |
|---|---|
| Sponsor | Sinocelltech Ltd. |
| Drug class | CD47/SIRPα axis inhibitor |
| Target | CD47/SIRPα axis |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SCTB14 works by blocking the interaction between CD47 and SIRPα, which is involved in tumor immune evasion. This blockade leads to the activation of immune cells and enhanced anti-tumor activity.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. (PHASE3)
- Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCTB14 CI brief — competitive landscape report
- SCTB14 updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI